The IBD SmartSelect Composite Rating for McKesson increased from 93 to 96 Tuesday.
The upgrade means the stock is now outpacing 96% of all other stocks in terms of key performance metrics and technical strength. The best stocks tend to have a 95 or better grade as they begin to launch a significant move so be sure to keep that in mind when looking for the best stocks to buy and watch.
McKesson is trading about 4% above a 632.59 entry from a cup with handle.
Looking For The Best Stocks To Buy And Watch? Start Here
The stock has an 86 EPS Rating, meaning its recent quarterly and annual earnings growth tops 86% of all stocks.
Its Accumulation/Distribution Rating of A shows heavy buying by institutional investors over the last 13 weeks.
In Q3, the company posted 4% earnings growth. Top line growth fell to 18%, down from 21% in the prior quarter.
McKesson holds the No. 2 rank among its peers in the Medical-Wholesale Drugs industry group. is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
